Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
暂无分享,去创建一个
Satoru Miyano | Rui Yamaguchi | Seiichiro Yamamoto | Koji Tsuta | Shun-ichi Watanabe | Hideaki Mizuno | Yoko Shimada | Hiromi Sakamoto | Noriko Gotoh | Koh Furuta | Akinori Sarai | Tatsuhiro Shibata | Jun Yokota | Takashi Kohno | Seiichi Takenoshita | Kensuke Kumamoto | S. Miyano | K. Kumamoto | J. Yokota | T. Kohno | T. Shibata | A. Sarai | R. Yamaguchi | H. Sakamoto | R. Iwakawa | K. Tsuta | N. Gotoh | S. Takenoshita | K. Shiraishi | Seiichiro Yamamoto | K. Furuta | Reika Iwakawa | Kouya Shiraishi | Hirokazu Okayama | H. Okayama | Yuko Ishii | Shuichi Kawano | Yoko Shimada | Y. Ishii | Shun‐ichi Watanabe | Shuichi Kawano | Hideaki Mizuno | Shun-ichi Watanabe | Shun-Ichi Watanabe | Reika Iwakawa
[1] Kenta Nakai,et al. PrognoScan: a new database for meta-analysis of the prognostic value of genes , 2009, BMC Medical Genomics.
[2] Keitaro Matsuo,et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Peter M Schlag,et al. Identification of early molecular markers for breast cancer , 2011, Molecular Cancer.
[4] Laura La Paglia,et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. , 2010, Cancer treatment reviews.
[5] T. Katagiri,et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis , 2007, Oncogene.
[6] Yusuke Nakamura,et al. Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells. , 2010, Cancer research.
[7] T. Mitsudomi,et al. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation , 2010, Cancer and Metastasis Reviews.
[8] Yi-long Wu,et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression , 2010, Molecular Cancer.
[9] Vidar Skaug,et al. The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non–Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts , 2011, Clinical Cancer Research.
[10] J. Cigudosa,et al. Expression signatures in lung cancer reveal a profile for EGFR‐mutant tumours and identify selective PIK3CA overexpression by gene amplification , 2008, The Journal of pathology.
[11] S. Davis,et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.
[12] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[13] Ping Yang,et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. , 2009, Human pathology.
[14] N. Girard,et al. New driver mutations in non-small-cell lung cancer. , 2011, The Lancet. Oncology.
[15] H. Ropers,et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes , 2010, Nature Genetics.
[16] H. Hansen,et al. Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.
[17] Y. Ishikawa,et al. Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.
[18] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[19] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[21] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Kurzrock,et al. Targeted therapy in non-small-cell lung cancer—is it becoming a reality? , 2010, Nature Reviews Clinical Oncology.
[23] M. Meyerson,et al. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Takayuki Kosaka,et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J H Lubin,et al. Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.
[26] J. Minna,et al. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. , 2010, Cancer cell.
[27] J. Robins,et al. More on "Biased selection of controls for case-control analyses of cohort studies". , 1986, Biometrics.
[28] A. Iafrate,et al. A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.
[29] A. Gazdar,et al. Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.
[30] Michalis V. Karamouzis,et al. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.
[31] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[32] T. Mitsudomi. Advances in target therapy for lung cancer. , 2010, Japanese journal of clinical oncology.
[33] Teruhiko Yoshida,et al. Epidermal Growth Factor Receptor Mutation Detection Using High-Resolution Melting Analysis Predicts Outcomes in Patients with Advanced Non–Small Cell Lung Cancer Treated with Gefitinib , 2007, Clinical Cancer Research.
[34] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[35] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[36] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[37] D B Richardson,et al. An incidence density sampling program for nested case-control analyses , 2004, Occupational and Environmental Medicine.
[38] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.